

Walter

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7498857/walter-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

207
papers

14,724
citations

65
h-index

116
g-index

215
ext. papers

16,475
ext. citations

5
avg, IF

6.48
L-index

#	Paper	IF	Citations
207	DSM-5 criteria for substance use disorders: recommendations and rationale. <i>American Journal of Psychiatry</i> , 2013 , 170, 834-51	11.9	784
206	Validation of the Alcohol, Smoking And Substance Involvement Screening Test (ASSIST). <i>Addiction</i> , 2008 , 103, 1039-47	4.6	626
205	The Clinical Opiate Withdrawal Scale (COWS). <i>Journal of Psychoactive Drugs</i> , 2003 , 35, 253-9	3.6	625
204	Structural abnormalities in the brains of human subjects who use methamphetamine. <i>Journal of Neuroscience</i> , 2004 , 24, 6028-36	6.6	574
203	Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. <i>New England Journal of Medicine</i> , 2003 , 349, 949-58	59.2	440
202	Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. <i>Lancet, The</i> , 2011 , 377, 1506-13	40	371
201	Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. <i>Archives of General Psychiatry</i> , 2011 , 68, 1238-46		371
200	Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. <i>Archives of General Psychiatry</i> , 2004 , 61, 73-84		308
199	Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. <i>Addiction</i> , 1998 , 93, 475-86	4.6	278
198	A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. <i>Archives of General Psychiatry</i> , 1996 , 53, 401-7		269
197	Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. <i>Addiction</i> , 2014 , 109, 79-87	4.6	256
196	Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. <i>Drug and Alcohol Dependence</i> , 2001 , 63, 139-46	4.9	236
195	Cognitive impairment in individuals currently using methamphetamine. <i>American Journal on Addictions</i> , 2000 , 9, 222-31	3.7	231
194	Hyperalgesic responses in methadone maintenance patients. <i>Pain</i> , 2001 , 90, 91-6	8	215
193	A comparison of contingency management and cognitive-behavioral approaches during methadone maintenance treatment for cocaine dependence. <i>Archives of General Psychiatry</i> , 2002 , 59, 817-24		208
192	A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. <i>Addiction</i> , 2005 , 100, 1090-100	4.6	182
191	A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals. <i>Addiction</i> , 2006 , 101, 267-74	4.6	181

190	Smoking cessation in methadone maintenance. <i>Addiction</i> , 2002 , 97, 1317-28; discussion 1325	4.6	181
189	Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 1440-8	4.6	171
188	Bupropion for the treatment of methamphetamine dependence. <i>Neuropsychopharmacology</i> , 2008 , 33, 1162-70	8.7	166
187	Methamphetamine abstinence syndrome: preliminary findings. <i>American Journal on Addictions</i> , 2004 , 13, 248-55	3.7	158
186	Sexual HIV risk among gay and bisexual male methamphetamine abusers. <i>Journal of Substance Abuse Treatment</i> , 1996 , 13, 483-6	4.2	158
185	An intensive outpatient approach for cocaine abuse treatment. The Matrix model. <i>Journal of Substance Abuse Treatment</i> , 1995 , 12, 117-27	4.2	155
184	Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. <i>American Journal of Drug and Alcohol Abuse</i> , 2011 , 37, 313-23	3.7	154
183	Cognitive performance of current methamphetamine and cocaine abusers. <i>Journal of Addictive Diseases</i> , 2002 , 21, 61-74	1.7	154
182	Methadyl acetate and methadone as maintenance treatments for heroin addicts. A veterans administration cooperative study. <i>Archives of General Psychiatry</i> , 1976 , 33, 709-20		154
181	Long-term course of opioid addiction. <i>Harvard Review of Psychiatry</i> , 2015 , 23, 76-89	4.1	151
180	A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. <i>Drug and Alcohol Dependence</i> , 1995 , 40, 125-31	4.9	150
179	Pain responses in methadone-maintained opioid abusers. <i>Journal of Pain and Symptom Management</i> , 2000 , 20, 237-45	4.8	148
178	A randomized controlled trial of a brief intervention for illicit drugs linked to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) in clients recruited from primary health-care settings in four countries. <i>Addiction</i> , 2012 , 107, 957-66	4.6	136
177	Will the methamphetamine problem go away?. <i>Journal of Addictive Diseases</i> , 2002 , 21, 5-19	1.7	133
176	Medications development: successes and challenges 2005 , 108, 94-108		131
175	Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. <i>Addiction</i> , 2016 , 111, 695-705	4.6	126
174	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine. <i>Pain</i> , 2001 , 93, 155-163	8	120
173	Prescription opioid abuse, pain and addiction: clinical issues and implications. <i>Drug and Alcohol Review</i> , 2011 , 30, 300-5	3.2	115

172	Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. <i>American Journal on Addictions</i> , 2004 , 13 Suppl 1, S42-66	3.7	114
171	Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2006 , 85, 12-8	4.9	112
170	Baclofen as a cocaine anti-craving medication: a preliminary clinical study. <i>Neuropsychopharmacology</i> , 1998 , 18, 403-4	8.7	111
169	Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2008 , 96, 222-32	4.9	111
168	Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 778-790 ⁴⁰		108
167	Cerebral metabolic dysfunction and impaired vigilance in recently abstinent methamphetamine abusers. <i>Biological Psychiatry</i> , 2005 , 58, 770-8	7.9	107
166	Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1576-83	27.4	106
165	A comparison of patterns of methamphetamine and cocaine use. <i>Journal of Addictive Diseases</i> , 2002 , 21, 35-44	1.7	105
164	The effect of relapse on cognition in abstinent methamphetamine abusers. <i>Journal of Substance Abuse Treatment</i> , 2004 , 27, 59-66	4.2	101
163	Substitution pharmacotherapies for opioid addiction: from methadone to LAAM and buprenorphine. <i>Journal of Psychoactive Drugs</i> , 1994 , 26, 119-28	3.6	101
162	Bupropion hydrochloride versus placebo, in combination with cognitive behavioral therapy, for the treatment of cocaine abuse/dependence. <i>Journal of Addictive Diseases</i> , 2008 , 27, 13-23	1.7	98
161	Clinical efficacy of buprenorphine: comparisons to methadone and placebo. <i>Drug and Alcohol Dependence</i> , 2003 , 70, S49-57	4.9	93
160	Contingency management for tobacco smoking in methadone-maintained opiate addicts. <i>Addictive Behaviors</i> , 1996 , 21, 409-12	4.2	93
159	Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region. <i>Addiction</i> , 2002 , 97, 771-2	4.6	91
158	Buprenorphine tapering schedule and illicit opioid use. <i>Addiction</i> , 2009 , 104, 256-65	4.6	90
157	Methamphetamine and cocaine users: differences in characteristics and treatment retention. <i>Journal of Psychoactive Drugs</i> , 2000 , 32, 233-8	3.6	90
156	Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START). <i>Journal of Studies on Alcohol and Drugs</i> , 2013 , 74, 605-13	1.9	86
155	Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. <i>Addiction</i> , 2013 , 108, 1628-37	4.6	83

154	Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2010 , 109, 20-9	4.9	82
153	Comparison of behavioral treatment conditions in buprenorphine maintenance. <i>Addiction</i> , 2013 , 108, 1788-98	4.6	81
152	Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. <i>Drug and Alcohol Dependence</i> , 2006 , 85, 177-84	4.9	77
151	Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. <i>Drug and Alcohol Dependence</i> , 1997 , 45, 131-4	4.9	76
150	Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: a randomized trial. <i>Drug and Alcohol Dependence</i> , 2013 , 128, 71-6	4.9	74
149	Traditional medicine in the treatment of drug addiction. <i>American Journal of Drug and Alcohol Abuse</i> , 2009 , 35, 1-11	3.7	72
148	Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy. <i>Journal of Pain</i> , 2012 , 13, 401-9	5.2	69
147	Diagnosing addictive disease in chronic pain patients. <i>Psychosomatics</i> , 1996 , 37, 223-35	2.6	69
146	A cooperative clinical study of methadyl acetate. I. Three-times-a-week regimen. <i>Archives of General Psychiatry</i> , 1978 , 35, 345-53		68
145	Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone. <i>Addiction</i> , 2013 , 108, 2141-9	4.6	67
144	Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. <i>Pain</i> , 2006 , 120, 267-275	8	65
143	Naltrexone and dysphoria: fact or myth?. <i>American Journal on Addictions</i> , 2002 , 11, 151-60	3.7	65
142	An intronic variant in OPRD1 predicts treatment outcome for opioid dependence in African-Americans. <i>Neuropsychopharmacology</i> , 2013 , 38, 2003-10	8.7	61
141	Status of methamphetamine users 2-5 years after outpatient treatment. <i>Journal of Addictive Diseases</i> , 2002 , 21, 107-19	1.7	61
140	Interest in smoking cessation among methadone maintained outpatients. <i>Journal of Addictive Diseases</i> , 1998 , 17, 9-19	1.7	60
139	Magnetic resonance imaging evidence of "silent" cerebrovascular toxicity in cocaine dependence. <i>Biological Psychiatry</i> , 1999 , 45, 1203-11	7.9	59
138	Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. <i>Clinical Neurophysiology</i> , 2003 , 114, 410-5	4.3	58
137	A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2010 , 31, 189-99	2.3	57

136	HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 66, 288-93	3.1	56
135	A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. <i>Drug and Alcohol Dependence</i> , 2008 , 97, 158-68	4.9	55
134	Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. <i>Psychiatry Research</i> , 2001 , 102, 227-33	9.9	54
133	Gabapentin improves cold-pressor pain responses in methadone-maintained patients. <i>Drug and Alcohol Dependence</i> , 2010 , 109, 213-9	4.9	52
132	Patient perspectives on buprenorphine/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. <i>Journal of Psychoactive Drugs</i> , 2014 , 46, 412-26	3.6	50
131	Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. <i>Drug and Alcohol Dependence</i> , 2009 , 99, 28-36	4.9	49
130	Effectiveness of drug dependence treatment in HIV prevention. <i>International Journal of Drug Policy</i> , 2005 , 16, 67-75	5.5	49
129	Buprenorphine: blending practice and research. <i>Journal of Substance Abuse Treatment</i> , 2002 , 23, 87-92	4.2	49
128	Cognitive deficits among methamphetamine users with attention deficit hyperactivity disorder symptomatology. <i>Journal of Addictive Diseases</i> , 2002 , 21, 75-89	1.7	48
127	Treatment for amphetamine withdrawal. <i>The Cochrane Library</i> , 2009 , CD003021	5.2	47
126	Management of methamphetamine abuse and dependence. <i>Current Psychiatry Reports</i> , 2006 , 8, 345-54	9.1	47
125	A screening trial of amantadine as a medication for cocaine dependence. <i>Drug and Alcohol Dependence</i> , 2002 , 66, 217-24	4.9	47
124	Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects. <i>Obesity</i> , 2007 , 15, 1717-31	8	46
123	A comparison of injecting and noninjecting methamphetamine users. <i>Journal of Psychoactive Drugs</i> , 2000 , 32, 229-32	3.6	46
122	Association between quantitative EEG and neurocognition in methamphetamine-dependent volunteers. <i>Clinical Neurophysiology</i> , 2004 , 115, 194-8	4.3	44
121	Cocaine abuse treatment: a review of current strategies. <i>Journal of Substance Abuse</i> , 1991 , 3, 457-91		41
120	Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. <i>Addiction</i> , 2014 , 109, 1489-500	4.6	40
119	Depressive symptoms, substance use, and HIV-related high-risk behaviors among opioid-dependent individuals: results from the Clinical Trials Network. <i>Substance Use and Misuse</i> , 2011 , 46, 1716-25	2.2	40

118	Cocaine infusion increases interferon-gamma and decreases interleukin-10 in cocaine-dependent subjects. <i>Clinical Immunology and Immunopathology</i> , 1998 , 89, 181-90		40
117	Neurobehavioral treatment for cocaine dependency. <i>Journal of Psychoactive Drugs</i> , 1990 , 22, 159-71	3.6	40
116	NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale. <i>Contemporary Clinical Trials</i> , 2016 , 50, 253-64	2.3	40
115	Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine. <i>Drug and Alcohol Dependence</i> , 2006 , 82, 25-31	4.9	39
114	Buprenorphine + Naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. <i>Addiction</i> , 2016 , 111, 1416-27	4.6	36
113	Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine + Naloxone and Methadone. <i>Journal of Addiction Medicine</i> , 2017 , 11, 63-69	3.8	35
112	A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. <i>Journal of Addiction Medicine</i> , 2013 , 7, 33-8	3.8	35
111	From research to the real world: buprenorphine in the decade of the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010 , 38 Suppl 1, S53-60	4.2	35
110	Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?. <i>Journal of Addiction Medicine</i> , 2015 , 9, 238-43	3.8	34
109	Effect of oral ketorolac and gender on human cold pressor pain tolerance. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2003 , 30, 759-63	3	33
108	Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). <i>Addiction</i> , 2005 , 100 Suppl 1, 78-90	4.6	33
107	Addiction pharmacotherapy 2000: new options, new challenges. <i>Journal of Psychoactive Drugs</i> , 2000 , 32, 371-8	3.6	33
106	Prescription of opioids for treatment of pain in patients with addictive disease. <i>Journal of Pain and Symptom Management</i> , 1993 , 8, 289-96	4.8	33
105	Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. <i>Neuropsychopharmacology</i> , 1999 , 20, 582-90	8.7	32
104	Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010 , 38 Suppl 1, S80-6	4.2	31
103	Integrating treatments for methamphetamine abuse: a psychosocial perspective. <i>Journal of Addictive Diseases</i> , 1997 , 16, 41-50	1.7	30
102	Testing and linkage to HIV care in China: a cluster-randomised trial. <i>Lancet HIV, the</i> , 2017 , 4, e555-e565	7.8	29
101	Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain. <i>Experimental and Clinical Psychopharmacology</i> , 2015 , 23, 428-35	3.2	29

100	Use of item response theory and latent class analysis to link poly-substance use disorders with addiction severity, HIV risk, and quality of life among opioid-dependent patients in the Clinical Trials Network. <i>Drug and Alcohol Dependence</i> , 2011 , 118, 186-93	4.9	29
99	Comparison of buprenorphine treatment for opioid dependence in 3 settings. <i>Journal of Addiction Medicine</i> , 2012 , 6, 68-76	3.8	29
98	Medication-assisted treatment for opioid addiction: methadone and buprenorphine. <i>Journal of Food and Drug Analysis</i> , 2013 , 21, S69-S72	7	28
97	Irritability following abstinence from cocaine predicts euphoric effects of cocaine administration. <i>Addictive Behaviors</i> , 2003 , 28, 817-21	4.2	27
96	The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction. <i>Substance Abuse and Rehabilitation</i> , 2012 , 3, 129-136	5.5	26
95	Opiate recidivism in a drug-treatment program: comparison of hair and urine data. <i>Journal of Analytical Toxicology</i> , 2003 , 27, 412-28	2.9	26
94	Cocaine abuse among methadone maintenance patients: are there effective treatment strategies?. <i>Journal of Psychoactive Drugs</i> , 1994 , 26, 129-36	3.6	26
93	Psychological approaches for the treatment of cocaine dependence--a neurobehavioral approach. <i>Journal of Addictive Diseases</i> , 1991 , 11, 97-119	1.7	26
92	Pharmacists and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2005 , 45, 23-32	1.7	25
91	Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. <i>Quality of Life Research</i> , 2012 , 21, 1177-83	3.7	24
90	A 3-year progress report on the implementation of LAAM in the United States. <i>Addiction</i> , 1998 , 93, 533-406	4.0	24
89	Participants receiving dehydroepiandrosterone during treatment for cocaine dependence show high rates of cocaine use in a placebo-controlled pilot study. <i>Experimental and Clinical Psychopharmacology</i> , 2004 , 12, 126-35	3.2	24
88	Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. <i>Synapse</i> , 2005 , 57, 113-5	2.4	24
87	Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. <i>Therapeutic Drug Monitoring</i> , 1997 , 19, 83-7	3.2	24
86	Cochrane systematic reviews in the field of addiction: what's there and what should be. <i>Drug and Alcohol Dependence</i> , 2011 , 113, 96-103	4.9	23
85	Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: have we chosen the best designs?. <i>Journal of Substance Abuse Treatment</i> , 2010 , 38 Suppl 1, S97-112	4.2	23
84	Lack of effect of chronic dextromethorphan on experimental pain tolerance in methadone-maintained patients. <i>Addiction Biology</i> , 2008 , 13, 393-402	4.6	23
83	Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users. <i>Journal of Substance Abuse Treatment</i> , 2015 , 48, 70-6	4.2	22

82	Predictors of outcome after short-term stabilization with buprenorphine. <i>Journal of Substance Abuse Treatment</i> , 2013 , 44, 336-42	4.2	22
81	Buprenorphine implant for opioid addiction. <i>Pain Management</i> , 2012 , 2, 345-50	2.3	22
80	Dancing with strangers: will U.S. substance abuse practice and research organizations build mutually productive relationships?. <i>Addictive Behaviors</i> , 2002 , 27, 941-9	4.2	22
79	Use of disulfiram for alcoholics in methadone maintenance programs. A Veterans Administration Cooperative Study. <i>Archives of General Psychiatry</i> , 1983 , 40, 851-4		22
78	Cocaine use reduction with buprenorphine (CURB): rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2013 , 34, 196-204	2.3	21
77	Using behavioral economics to predict opioid use during prescription opioid dependence treatment. <i>Drug and Alcohol Dependence</i> , 2015 , 148, 62-8	4.9	21
76	Participant characteristics and buprenorphine dose. <i>American Journal of Drug and Alcohol Abuse</i> , 2011 , 37, 453-9	3.7	21
75	Buprenorphine for opioid dependence. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 609-16	4.3	21
74	Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence. <i>Journal of Addictive Diseases</i> , 1995 , 14, 97-114	1.7	21
73	Treatment for amphetamine psychosis. <i>The Cochrane Library</i> , 2009 , CD003026	5.2	20
72	Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine. <i>Drug and Alcohol Dependence</i> , 2003 , 69, 317-22	4.9	20
71	The CSAT methamphetamine treatment program: research design accommodations for "real world" application. <i>Journal of Psychoactive Drugs</i> , 2000 , 32, 149-56	3.6	20
70	Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial. <i>PLoS ONE</i> , 2015 , 10, e0127598	3.7	20
69	Double-blind placebo-controlled evaluation of the PROMETA protocol for methamphetamine dependence. <i>Addiction</i> , 2012 , 107, 361-9	4.6	19
68	Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. <i>Addiction</i> , 2017 , 112, 1202-1209	4.6	18
67	Injectable extended-release naltrexone for opioid dependence. <i>Lancet, The</i> , 2011 , 378, 665; author reply 666	4.0	18
66	Buprenorphine 101: treating opioid dependence with buprenorphine in an office-based setting. <i>Journal of Addictive Diseases</i> , 2007 , 26, 93-9	1.7	18
65	Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study. <i>Journal of Substance Abuse Treatment</i> , 2020 , 110, 1-8	4.2	18

64	Comparing buprenorphine induction experience with heroin and prescription opioid users. <i>Journal of Substance Abuse Treatment</i> , 2012 , 43, 285-90	4.2	17
63	Effects of selegiline pretreatment on response to experimental cocaine administration. <i>Psychiatry Research</i> , 1999 , 87, 101-6	9.9	17
62	Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study. <i>Journal of Addiction Medicine</i> , 2019 , 13, 442-449	3.8	17
61	Alcohol and drug dependence symptom items as brief screeners for substance use disorders: results from the Clinical Trials Network. <i>Journal of Psychiatric Research</i> , 2012 , 46, 360-9	5.2	15
60	The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample. <i>American Journal on Addictions</i> , 2014 , 23, 343-8	3.7	14
59	Integration of research in pharmacotherapy for addictive disease: where are we? Where are we going?. <i>Journal of Addictive Diseases</i> , 1997 , 16, 83-102	1.7	14
58	Restabilization with methadone after methadyl acetate maintenance. <i>Archives of General Psychiatry</i> , 1980 , 37, 194-6		14
57	Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation. <i>Substance Abuse and Rehabilitation</i> , 2019 , 10, 69-78	5.5	14
56	Conducting clinical research with prescription opioid dependence: defining the population. <i>American Journal on Addictions</i> , 2010 , 19, 141-6	3.7	13
55	Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy. <i>Journal of Ethnicity in Substance Abuse</i> , 2010 , 9, 106-14	1.1	13
54	United Nations Office on Drugs and Crime International Network of Drug Dependence Treatment and Rehabilitation Resource Centres: Treatnet. <i>Substance Abuse</i> , 2010 , 31, 251-63	3.8	13
53	Health conditions in methamphetamine-dependent adults 3 years after treatment. <i>Journal of Addiction Medicine</i> , 2009 , 3, 155-63	3.8	13
52	The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacity. <i>Addiction</i> , 2007 , 102 Suppl 1, 107-13	4.6	13
51	Patient perspectives of opiate withdrawal. <i>Drug and Alcohol Dependence</i> , 1983 , 12, 167-72	4.9	13
50	Recent advances in the treatment of opiate addiction. <i>Clinical Neuroscience Research</i> , 2005 , 5, 161-167		12
49	Thin-layer Chromatography and Enzyme Immunoassay of L-Alpha-Acetyl Methadol and Methadone Metabolites in Urine. <i>Clinical Chemistry</i> , 1975 , 21, 109-112	5.5	12
48	Injectable pharmacotherapy for opioid use disorders (IPOD). <i>Contemporary Clinical Trials</i> , 2016 , 49, 70-7	2.3	10
47	Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. <i>Journal of Addiction Medicine</i> , 2016 , 10, 236-43	3.8	10

46	New trends in opiate pharmacotherapy. <i>Drug and Alcohol Review</i> , 2001 , 20, 79-94	3.2	10
45	Buprenorphine as a Pharmacotherapy for Opiate Addiction What Dose Provides a Therapeutic Response?. <i>American Journal on Addictions</i> , 1996 , 5, 220-230	3.7	10
44	Opioid addiction treatment modalities and some guidelines to their optimal use. <i>Journal of Psychoactive Drugs</i> , 1991 , 23, 151-63	3.6	10
43	Remission from chronic opioid use-Studying environmental and socio-economic factors on recovery (RECOVER): Study design and participant characteristics. <i>Contemporary Clinical Trials</i> , 2019 , 76, 93-103	2.3	10
42	A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here. <i>Journal of NeuroImmune Pharmacology</i> , 2016 , 11, 394-400	6.9	9
41	Advances in opioid antagonist treatment for opioid addiction. <i>Psychiatric Clinics of North America</i> , 2012 , 35, 297-308	3.1	9
40	Neuropsychological and diagnostic differences between recidivistically violent not criminally responsible and mentally ill prisoners. <i>International Journal of Law and Psychiatry</i> , 2000 , 23, 161-72	2.6	9
39	Loss to Follow-Up from HIV Screening to ART Initiation in Rural China. <i>PLoS ONE</i> , 2016 , 11, e0164346	3.7	9
38	Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone. <i>Journal of Addiction Medicine</i> , 2012 , 6, 118-23	3.8	8
37	Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. <i>American Journal of Drug and Alcohol Abuse</i> , 2008 , 34, 611-6	3.7	8
36	A cooperative clinical study of methadyl acetate. II. Friday-only regimen. <i>Archives of General Psychiatry</i> , 1980 , 37, 908-11		8
35	Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2018 , 44, 488-496	3.7	7
34	Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes. <i>Journal of Addictive Diseases</i> , 2010 , 29, 23-9	1.7	7
33	HIV/AIDS and drug use in China--interactions, impacts, and issues. <i>Substance Use and Misuse</i> , 2012 , 47, 1015-25	2.2	7
32	Pharmacokinetics of buprenorphine: a comparison of sublingual tablet versus liquid after chronic dosing. <i>Journal of Addiction Medicine</i> , 2007 , 1, 88-95	3.8	7
31	Apathy predicts hedonic but not craving response to cocaine. <i>Pharmacology Biochemistry and Behavior</i> , 2005 , 82, 236-40	3.9	7
30	Depressive illness in childhood presenting as severe headache. <i>JAMA Pediatrics</i> , 1970 , 120, 122-4		7
29	Integration of Research in Pharmacotherapy for Addictive Disease:. <i>Journal of Addictive Diseases</i> , 1997 , 16, 83-102	1.7	7

28	Medication-assisted therapy for opioid addiction. <i>Journal of Food and Drug Analysis</i> , 2013 , 21, S13-S15	7	6
27	Prescription opioid addiction and chronic pain: More than a feeling. <i>Drug and Alcohol Dependence</i> , 2017 , 173 Suppl 1, S73-S74	4.9	6
26	Variation in neurophysiological function and evidence of quantitative electroencephalogram discordance: predicting cocaine-dependent treatment attrition. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006 , 18, 208-16	2.7	6
25	Diffusion of substance abuse treatment: will buprenorphine be a success?. <i>Journal of Psychoactive Drugs</i> , 2004 , Suppl 2, 115-7	3.6	5
24	Urine toxicology as an outcome measure in drug abuse clinical trials: must every sample be analyzed?. <i>Journal of Addictive Diseases</i> , 1996 , 15, 85-92	1.7	5
23	Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China. <i>Neuroscience Bulletin</i> , 2016 , 32, 538-544	4.3	5
22	Measuring recovery in opioid use disorder: clinical utility and psychometric properties of the Treatment Effectiveness Assessment. <i>Substance Abuse and Rehabilitation</i> , 2019 , 10, 13-21	5.5	4
21	Outcome study: comparison of short-term vs long-term treatment in a residential community. <i>Substance Use and Misuse</i> , 1992 , 27, 15-23		4
20	Current status of the evaluation of LAAM as a maintenance drug for heroin addicts. <i>American Journal of Drug and Alcohol Abuse</i> , 1975 , 2, 307-15	3.7	4
19	Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003. <i>Drug and Alcohol Dependence</i> , 2015 , 152, 218-23	4.9	3
18	Care cascade structural intervention versus standard of care in the diagnosis and treatment of HIV in China: a cluster-randomized controlled trial protocol. <i>BMC Health Services Research</i> , 2017 , 17, 397	2.9	3
17	Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2009 , 35, 311-5	3.7	3
16	Cynthia's Dilemma. <i>American Journal of Bioethics</i> , 2002 , 2, 55-6	1.1	3
15	Medications in the treatment of addictive disease. <i>Journal of Psychoactive Drugs</i> , 1991 , 23, 365-70	3.6	3
14	Alternative induction and crossover schedules for methadyl acetate. <i>Archives of General Psychiatry</i> , 1984 , 41, 193-9		3
13	Substance Abuse: Sedative, Hypnotic, or Anxiolytic Use Disorders		3
12	DSM-V: time for change. <i>Addiction</i> , 2011 , 106, 872-3; discussion 895-7	4.6	2
11	LONG-SUFFERING OR PROLONGED SUFFERING? TIME MATTERS. <i>Addiction</i> , 2009 , 104, 1429-1430	4.6	2

10	Substance use and treatment options in Cambodia. <i>Drug and Alcohol Review</i> , 2004 , 23, 365-7	3.2	2
9	Women on LAAM maintenance: initial experiences. <i>Journal of Psychedelic Drugs</i> , 1979 , 11, 223-9		2
8	An Updated Version of the Treatment Effectiveness Assessment (TEA) [Letter]. <i>Substance Abuse and Rehabilitation</i> , 2020 , 11, 21-22	5.5	1
7	Buprenorphine for opioid addiction. <i>Neuropsychiatry</i> , 2013 , 3, 535-543	1.8	1
6	Prescription drug overdose: between patients and their doctors. <i>Substance Abuse and Rehabilitation</i> , 2013 , 4, 1-2	5.5	1
5	The Treatment Effectiveness Assessment (TEA). <i>Substance Abuse and Rehabilitation</i> , 2013 , 4, 73-4	5.5	1
4	Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose. <i>Pain Medicine</i> , 2020 , 21, 2007-2008	2.8	1
3	A clinical physiologic correlate of voluntary gaze palsy, optokinetic nystagmus, and vestibular nystagmus. <i>American Journal of Ophthalmology</i> , 1970 , 69, 437-9	4.9	0
2	Commentary on Brooner et al. (2013): one-stop shopping--what sells and what doesn't. <i>Addiction</i> , 2013 , 108, 1952-3	4.6	
1	Why we do what we do-delivery of buprenorphine and the treatment of opioid addiction. <i>Addiction</i> , 2007 , 102, 1908-9	4.6	